THC Global has announced its first Australian-made medicinal cannabis product is now available via prescription.
Launched under the Canndeo brand, the CBD medicine uses cannabis sourced from THC’s Bundaberg growing plant and manufactured as its Southport base.
The company’s medical and clinical affairs team, CanndeoCare, will support
doctors, pharmacists and other healthcare professionals in prescribing the drug.
It will also be accessible via THC’s newly acquired clinic network Tetra Health.
THC Global CEO, Ken Charteris said: “Getting our wholly Australian medicinal cannabis product to be available for prescribing by Australian doctors is a real milestone… We look forward to increasing the number of Australian patients able to access medicinal cannabis by providing an affordable medicine.”